Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial.

ABSTRACT:

Importance

Uncertainty remains about the efficacy of intravenous iron in patients with heart failure and iron deficiency.

Objective

To assess the efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency.

Design, setting, and participants

This multicenter, randomized clinical trial enrolled 1105 patients with heart failure (defined as having a left ventricular ejection fraction of ≤45%) and iron deficiency (serum ferritin level <100 ng/mL; or if transferrin saturation was <20%, a serum ferritin level between 100 ng/mL and 299 ng/mL) at 70 clinic sites in 6 European countries from March 2017 to November 2023. The median follow-up was 16.6 months (IQR, 7.9-29.9 months).

Intervention

Administration of ferric carboxymaltose (n 

SUBMITTER: Anker SD 

PROVIDER: S-EPMC11955906 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature